Switzerland

After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region

Bond issuance and extended revolving credit facility provide financial headroom as the company restructures operations to accelerate biosimilars growth while maintaining generics scale.

The Swiss biotech’s shares jumped by 27% after the US agency said another trial was not needed to submit sonelokimab.

As 2025 turns to 2026, Swiss medtechs are anxiously looking to the future on three major fronts, according to Daniel Delfosse, head of regulation and innovation at the national industry association, Swiss Medtech.

The Switzerland-based group’s alpha-synuclein-targeted immunotherapy shows promise in slowing progression of the degenerative brain condition.

The Swiss group is more than holding its own against Dupixent for prurigo nodularis and is looking to make further inroads into Sanofi and Regeneron's blockbuster's market share in atopic dermatitis.

With a “sharpened focus,” Polpharma Biologics has spun out its contract development and manufacturing business into a separate company.

The Swiss company remains bullish about the drug’s prospects for hidradenitis suppurativa but its stock has collapsed by 90% after hit-and-miss Phase III trial results.

Swiss medtechs have given overwhelming support for an ongoing bilateral approach between Switzerland and the EU, as proposed in the Swiss-EU Package in June. A medtech MRA is the ultimate prize, but that remains some way off.

The UDI devices module in swissdamed is now live and can be used on a voluntary basis until it becomes mandatory in mid-2026.

Generics Bulletin reviews global regulatory developments across the world.